LTP Shares LTR Pharma Limited
ASX · ASXLast in our picks 2026-10-04 — not in the current list; analysis below is from that screen
Seasonal demand and test utilization expansion can drive a near-term bounce.
Signal breakdown
- ▸Upcoming respiratory season catalyst.
- ▾Below 50-day MA (-1.44%)
Is LTP a buy right now?
Trend: LTP is trading below the 50-day average (-6.38%), RSI 49 — neutral momentum, with a 3-month return of -2.22%.
Valuation & quality: LTR Pharma Limited trades on price-to-book 3.96; fundamentals show net margin 0.0%, return on equity -54.7%, revenue growth -38.5% year on year.
Our screen: ACCUMULATE (score 1) — Seasonal demand and test utilization expansion can drive a near-term bounce.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.90% | +0.00% | -7.30% | +44.70% | -14.50% | +6.40% | -4.00% | -8.30% |
Fundamentals
Technical signals
About LTR Pharma Limited
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.